1-7 of 7
Tomoaki Fujisaki, MD, PhD
Close
Sort by
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Maria-Victoria Mateos, Michele Cavo, Joan Bladé, MD PhD, Meletios A. Dimopoulos, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, MD FRCP, FRCPath, Maria Krevvata, PhD, Jianping Wang, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Rachel Kobos, MD, Jesús San-Miguel
Journal: Blood
Blood (2019) 134 (Supplement_1): 859.
https://doi.org/10.1182/blood-2019-123401
Published: 2019
Journal Articles

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Koji Nagafuji, MD PhD, Toshihiro Miyamoto, MD PhD, Tetsuya Eto, MD PhD, Ryosuke Ogawa, MD PhD, Naoyuki Uchida, MD PhD, Ken Takase, MD, Noriaki Kawano, MD PhD, Tomoaki Fujisaki, MD PhD, Tomohiko Kamimura, MD PhD, Atsushi Wake, MD PhD, Hirokazu Okumura, MD PhD, Yasuhiko Miyazaki, MD PhD, Yasushi Takamatsu, MD PhD, Toshiro Kurokawa, MD PhD, Yuju Ohno, MD PhD, Shouhei Yokota, MP.Path, Koichi Akashi, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3970.
https://doi.org/10.1182/blood-2018-99-112848
Published: 2018
Journal Articles

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Yoshiaki Tomiyama, MD, Jun Ho Jang, MD PhD, Jong-Wook Lee, MD PhD, Koji Miyazaki, MD, Koji Nagafuji, MD PhD, Kensuke Usuki, MD PhD, Nobuhiko Uoshima, MDPhD, Tomoaki Fujisaki, MD PhD, Hiroshi Kosugi, MD PhD, Itaru Matsumura, MD, Ko Sasaki, MD PhD, Masahiro Kizaki, MDPhD, Masashi Sawa, MD PhD, Michihiro Hidaka, MD PhD, Naoki Kobayashi, MD PhD, Satoshi Ichikawa, MD, Yuji Yonemura, MDPhD, Hiroyuki Keta, Akira Matsuda, MD, Keiya Ozawa, MD, Kinuko Mitani, MD, Shinji Nakao, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1306.
https://doi.org/10.1182/blood-2018-99-112478
Published: 2018
Journal Articles

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

Meletios A Dimopoulos, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, Zsolt Nagy, MD PhD, Polina Kaplan, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, MD, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, Christopher Chiu, PhD, Jianping Wang, Anupa Kudva, Rachel Kobos, MD, Susan Wroblewski, PhD, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD, Joan Bladé, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 156.
https://doi.org/10.1182/blood-2018-156
Published: 2018
Journal Articles

Prognostic Significance Of S-Phase Kinase-Associated Protein 2 (Skp2) In DLBCL Patients Treated With Upfront Autologous Peripheral Blood Stem Cell Transplantation

Takashi Okamura, MD, PhD, Ritsuko Seki, PhD, Koji Nagafuji, MD, PhD, Kisato Nosaka, MD, PhD, Takeshi Tsuchiya, MD, PhD, Hiroyuki Tsuda, M.D, PhD, Toshihiro Miyamoto, MD, Masakazu Higuchi, MD, PhD, Hitoshi Suzushima, MD, PhD, Michihiro Hidaka, MD, PhD, Abe Yasunobu, MD, PhD, Yuji Yufu, MD, PhD, Yutaka Imamura, MD, PhD, Masahiro Iwahashi, MD, PhD, Tomoaki Fujisaki, MD, PhD, Naokuni Uike, MD, PhD, Moriuchi Yukiyoshi, MD, PhD, Tetsuya Eto, MD, PhD, Gondo Hisashi, MD, PhD, Tomohiko Kamimura, MD PhD, Yasushi Takamatsu, MD, PhD, Ohshima Koichi, MD PhD
Journal: Blood
Blood (2013) 122 (21): 3022.
https://doi.org/10.1182/blood.V122.21.3022.3022
Published: 2013
Journal Articles

Minimal Residual Disease Negative Status At the End of Induction Therapy Is a Potent Prognostic Marker in Adult Non-Ph Acute Lymphoblastic Leukemia: Results of the ALL MRD2002 Study

Koji Nagafuji, MD, PhD, Toshihiro Miyamoto, MD, PhD, Tetsuya Eto, MD, PhD, Tomohiko Kamimura, MD, Shuichi Taniguchi, MD, PhD, Takashi Okamura, MD, PhD, Eiichi Ohtsuka, MD, PhD, Takashi Yoshida, MD, Masakazu Higuchi, MD, PhD, Goichi Yoshimoto, MD, PhD, Tomoaki Fujisaki, MD, PhD, Yasunobu Abe, MD, PhD, Yasushi Takamatsu, MD, PhD, Shouhei Yokota, MD, PhD, Koichi Akashi, MD, PhD., Mine Harada, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2581.
https://doi.org/10.1182/blood.V118.21.2581.2581
Published: 2011
Journal Articles

Prospective Multicenter Phase II Study of Myeloablative Conditioning Consisted of Intravenous Busulfan and Fludarabine +/− Total Body Irradiation for Older Patients (55 years and older): Results of the JSCT FB09 Study.

Naoyuki Uchida, MD, Michihiro Hidaka, MD, Toru Sakura, MD, Toshihiro Miyamoto, MD, PhD, Tomoaki Fujisaki, MD, PhD, Tetsuya Eto, MD, PhD, Yoshinobu Maeda, MD, PhD, Kenji Fukuno, MD, PhD, Kana Matsumoto, PhD, Kunihiko Morita, PhD, Junji Kishimoto, PhD, Takahiro Fukuda, MD, PhD, Takanori Teshima, MD, PhD, Shuichi Taniguchi, MD, PhD, Shin-Ichiro Mori, MD, Mine Harada, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3477.
https://doi.org/10.1182/blood.V116.21.3477.3477
Published: 2010